Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA4 | P22748 | 1/20 | 0.61 |
| ▸ | CA6 | P23280 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | TPMT | P51580 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11245183 | 0.95 | HDAC6 (0.69) | HDAC6MAPTTSHRCA12CA1 | |
| Dodecyl 3,4-Dimethoxybenzoate SCHEMBL7801796 | 0.94 | HDAC6 (0.69) | HDAC6MAPTTSHRKDM4EPOLB | |
| SCHEMBL20918131 | 0.94 | HDAC6 (0.69) | HDAC6MAPTTSHRKDM4EPOLB | |
| SCHEMBL7959660 | 0.93 | HDAC6 (0.68) | HDAC6MAPTTSHRCA12CA1 | |
| SCHEMBL11493630 | 0.93 | HDAC6 (0.68) | HDAC6MAPTTSHRCA12CA1 | |
| SCHEMBL27516230 | 0.92 | HDAC6 (0.67) | HDAC6MAPTTSHRCA12CA1 | |
| SCHEMBL11245864 | 0.91 | MAPT (0.73) | HDAC6MAPTTSHRCA12CA1 | |
| SCHEMBL7956506 | 0.91 | HDAC6 (0.65) | HDAC6MAPTTSHRCA12CA1 | |
| SCHEMBL11488776 | 0.91 | HDAC6 (0.65) | HDAC6MAPTTSHRCA12CA1 | |
| SCHEMBL11493970 | 0.91 | HDAC6 (0.65) | HDAC6MAPTTSHRCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110280940-A1 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy | KISS ROBERT (BE) | 2011-11-17 | — | — | US | claimed |
| EP-2367545-A1 | DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY | Université Libre de Bruxelles (BE) | 2011-09-28 | — | — | EP | claimed |
| WO-2010043631-A1 | DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2010-04-22 | — | — | WO | claimed |
| US-20110280940-A1 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy | KISS ROBERT (BE) | 2011-11-17 | — | — | US | disclosed |
| US-20110280940-A1 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy | KISS ROBERT (BE) | 2011-11-17 | — | — | US | disclosed |
| EP-2367545-A1 | DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY | Université Libre de Bruxelles (BE) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010043631-A1 | DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043631-A1 | DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280940-A1 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy | PSEN2, PSEN1, VHL | HDAC6 937/4885MAPT 42/4885TSHR 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.